Roles of HDACs in chromatin remodelling and response to chemotherapy in cancer
dc.contributor.advisor
Harrison, David
en
dc.contributor.advisor
Faratian, Dana
en
dc.contributor.author
Huang, Rui
en
dc.contributor.sponsor
University of Edinburgh
en
dc.contributor.sponsor
China Scholarships Council
en
dc.date.accessioned
2014-10-27T15:11:34Z
dc.date.available
2014-10-27T15:11:34Z
dc.date.issued
2014-07-05
dc.description.abstract
BACKGROUND:
The higher-order structure of chromatin changes in response to
extracellular and environmental signals. We observed nuclear morphological
changes in biopsied cancer tissue after chemotherapy. Since chromatin structure
dictates gene expression, and therefore function, further investigation of this
phenomenon may increase our understanding of therapeutic responses.
I
hypothesised that nuclear morphological changes in cancer in response to DNA-damage
by chemotherapy are mediated by histone deacetylases (de Ruijter, van
Gennip et al.). Methods: Ovarian cancer cell lines PEO1/PEO4 (platinum
sensitive/resistant) were selected as in vitro models, and primary ovarian cancer
xenografts OV1002 and HOX424 as in vivo models. Expression levels of HDACs,
heterochromatin protein 1 (HP1), and DNA damage response (DDR) proteins were
profiled by Western blot analysis after treatment with cisplatin.
Immunofluorescence
imaging was undertaken using confocal microscopy, and nuclear texture and γH2AX
foci were measured in Image J. Cell cycle and apoptosis were detected by flow
cytometry. Thirty eight different ovarian cancer biopsies and 175 xenograft samples
were assessed for HDAC and HP1 expression in response to chemotherapy by
quantitative immunofluorescence. HDAC2 expression was modulated by interfering
RNAs (siRNA). Results: I demonstrated nuclear morphological changes in clinical
tumours, xenografts, and cell lines in response to platinum chemotherapy by robust
measurement of nuclear texture. Expression of HDAC2 increased in PEO1 cells
treated with cisplatin at 24h, and this was accompanied by high expression of HP1s.
Expression of components of both HDACs and DDR pathways (pBRCA1, γH2AX,
pATM, pATR) showed time dependent changes after cisplatin treatment.
Knockdown of HDAC2 reduced the expression of HP1, induced DNA double strand
breaks (DSB) measured by γH2AX, and interfered with the activation of DDR
induced by cisplatin. Furthermore, HDAC2 depletion affected γH2AX foci formation,
cell cycle distribution, and apoptosis triggered by cisplatin, and was additive to the
inhibitory effect of cisplatin in cell lines. By inhibiting expression of HDAC2, I
observed reversible alteration of chromatin patterns during cisplatin treatment to
some degree. In clinical ovarian cancer specimens, expression of HDAC4, HDAC8
and HP1γ significantly increased after chemotherapy in sensitive patients, with
enhanced heterogeneity in chromatin pattern. HDAC2, HDAC8, and HP1 expression
were also increased after carboplatin treatment in carboplatin-sensitive xenografts.
CONCLUSION:
These results demonstrate alterations in nuclear morphology after
chemotherapy, and implicate HDACs in having a role in higher order chromatin
changes and in cellular DNA damage responses in ovarian cancer both in vitro and in
vivo.
en
dc.identifier.uri
http://hdl.handle.net/1842/9626
dc.language.iso
en
dc.publisher
The University of Edinburgh
en
dc.subject
HDAC
en
dc.subject
chromatin remodeling
en
dc.subject
chemotherapy
en
dc.title
Roles of HDACs in chromatin remodelling and response to chemotherapy in cancer
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Doctoral
en
dc.type.qualificationname
PhD Doctor of Philosophy
en
Files
Original bundle
1 - 1 of 1
- Name:
- Huang2014.pdf
- Size:
- 53.1 MB
- Format:
- Adobe Portable Document Format
- Description:
- one year restriction
This item appears in the following Collection(s)

